Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
17 hedge funds and large institutions have $13.1M invested in Timber Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 3 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
3% more capital invested
Capital invested by funds: $12.7M → $13.1M (+$350K)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$862K |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$749K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$235K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$183K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$131K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$648K |
| 2 |
SCM
Sio Capital Management
New York
|
-$158K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$58K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.71K |
TMBR Hedge Fund Activity: Q2 2017 in Review
17 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2017, worth a combined $13.1M — up 2.7% from $12.7M a quarter earlier.
Fund positioning in TMBR was balanced in Q2 2017: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $862K. The largest seller was RTW Investments, exiting entirely with an estimated $648K sold.
- 17 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $13.1M of Timber Pharmaceuticals, Inc. stock for Q2 2017, up 2.7% quarter-over-quarter.
- 3 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2017 and 3 closed out, a net change of 0 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2017 was Vanguard Group, an estimated $862K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2017 was RTW Investments, an estimated $648K sold.
Based on aggregated 13F filings for Q2 2017.